# BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies

> **NCT02090543** · — · COMPLETED · sponsor: **Bayer** · enrollment: 647 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Phenprocoumon (Marcumar)
- **DRUG:** Rivaroxaban (Xarelto, BAY-59 7939)

## Key facts

- **NCT ID:** NCT02090543
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-09
- **Final completion:** 2014-10
- **Target enrollment:** 647 (ACTUAL)
- **Last updated:** 2017-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02090543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02090543, "BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02090543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*